Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2026 May 8;6(5):e0006421. doi: 10.1371/journal.pgph.0006421

Bacterial diversity and antibiotic susceptibility profile of the isolates from public vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal

Ram Bahadur Khadka 1,*, Balram Neupane 1, Khimdhoj Karki 1, Saksham Pokharel 1
Editor: Julia Robinson2
PMCID: PMC13155621  PMID: 42101977

Abstract

Public transportation systems are vital for urban mobility but are susceptible to bacterial contamination due to high passenger density, frequent shared surface contact,minimal ventilation, and unsatisfactory cleaning practices promoting transmission of pathogenic and antibiotic resistant bacteria.,The main aim of this study was to explore the bacterial diversity associated with selected public vehicles and determine the antibiotics susceptibility patterns of bacterial isolates.A descriptive cross-sectional study was carried out from July 2023 to July 2024 at Paschimanchal Bus Terminal Stop, Butwal Sub-Metropolitan City, Rupandehi, Nepal. A total of 324 swabs were gathered from high-contact surfaces in AC buses, micro buses, and wingers using systematic sampling. Standard laboratory methods were used to identify bacterial cultures and their antibiotic susceptibility.Out of 324 surface swabs from 81 public vehicles, 262 (80.86%) showed bacterial growth. Among 262 isolates 148 (56.48%) were Gram positive and 114 (43.51%) Gram-negative. Predominant Gram positive isolates were CoNS 72 (27.48%), S.aureus 52 (19.84%) and Bacillus spp. 21 (8.02%), while Gram negative included E.coli 32 (12.21%), Klebsiella spp. 26 (9.92%) and Pseudomonas spp. 21 (8.02%). CoNS (44.44%, 32/72) and S.aureus (42.31%, 22/52) were significantly more frequent in Micro buses (P < 0.05). High antibiotic sensitivity was found for Gentamicin (100%, 12/12 for Micrococcus sp.; 97.22%, 70/72 for CoNS) and Meropenem (100%, 26/26 for Klebsiella spp.). Resistance was highest to Cetriaxone (100%, 9/9 for Citrobacter spp.) and Amoxicillin-clavulanic acid (69.2%. 18/26 for Klebsiella spp.) The extensive bacterial contamination present indicates an immediate need for better hygiene practices, improved cleaning methods, and public education to limit the microbial hazards associated with public transportation. Reduced sensitivity to commonly prescribed antibiotics, such as erythromycin in Staphylococcus aureus, indicates emerging antimicrobial resistance, posing greater risks to public health through limited treatment options and the spread of resistant strainsin the community.

Introduction

Public transportation systems facilitate mobility and connectivity in urban environments worldwide [1]. However, alongside their convenience, these shared spaces also harbor a hidden threat of bacterial contamination. From buses to taxis, tricycles to metro-buses, the surfaces of public vehicles serve as fertile breeding grounds for a diverse array of microorganisms, including potentially harmful pathogens [2]. Studies conducted across different regions including Istanbul city (Turkey) and Quito city (Ecuador) have consistently highlighted the presence of elevated levels of microbial diversity within these vehicles, raising concerns about the implications for public health [3,4].

The findings of these studies underscore the pervasive nature of bacterial contamination within public transportation systems. For instance, research conducted in Istanbul, Turkey, revealed that handles and surfaces in buses and metro buses were teeming with Staphylococcus aureus, coagulase-negative staphylococcus, and Enterococcus spp., highlighting the potential for these vehicles to serve as reservoirs for harmful microbes [3,5]. Similarly, studies conducted in other regions, such as Ghana and Nepal, have identified the presence of Escherichia coli, Salmonella spp., and methicillin-resistant Staphylococcus aureus (MRSA) on surfaces within public transport vehicles, further emphasizing the widespread nature of bacterial contamination [6–8].The implications of bacterial contamination in public transportation extend beyond immediate health risks to passengers. The presence of pathogenic bacteria raises concerns about the potential for disease transmission within communities, particularly in densely populated urban areas [9].

Public transport plays a significant role in the spread of antibiotic-resistant bacteria in cities due to the high number of people using these systems daily [10]. Understanding how these bacteria respond to antibiotics is crucial for planning effective strategies to prevent infections. A prior investigation reported number of drug resistance bacteria including Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli and Enterobacter spp. on public vehicles in Dhaka City, Bangladesh [11]. Marked similarly, studies in Mekelle, Ethiopia [12], and in Portland, USA [13] identified antibiotic resistant bacterial isolates from public transport systems. These studies further emphasize the worldwide nature of the public health problem. Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), has been found in buses and subways, with about 65% of MRSA strains showing resistance to multiple antibiotics [14]. Similarly, Klebsiella pneumoniae resistant to carbapenems and E. coli resistant to colistin due to the mcr-1 gene have been detected. Other bacteria, such as Enterococcus faecium and Enterococcus faecalis, are also common on public transport surfaces and often show resistance to several antibiotics [15–17].

Addressing the issue of bacterial contamination in public transportation requires a comprehensive approach. This includes the implementation of rigorous cleaning and disinfection protocols, as well as the promotion of personal hygiene practices among passengers. Additionally, the development of innovative solutions, such as antimicrobial surface coatings, holds promise for reducing the prevalence of pathogenic bacteria in these environments [18,19]. Furthermore, raising awareness among the general population about the risks associated with microbial contamination in public transport is essential in promoting behavior change and fostering a culture of cleanliness and hygiene [13,20]. Therefore the present study aimed to determine Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal.

Materials and methods

Ethics statement

This present study was conducted on environmental samples, collected from public vehicles. No human participants or animals were involved in the research. The individuals pictured in the supporting information files have provided written informed consent (as outlined in PLOS consent form) to publish their image.Research approval for this study was obtained from the Pokhara University Research Center (PURC),Pokhara University,Kaski,Nepal (Approval/Grant No. 02-2079/80).

Study site

A descriptive cross-sectional study was conducted at Paschimanchal Bus Terminal Stop, Butwal Sub-Metropolitan City, Rupandehi, Nepal, from July 2023 toJuly 2024. This urban transportation hub serves as a central point for commuters traveling within the city, neighbouring cities, and districts.

Collection and processing of the sample

A systematic sampling approach was utilized to collect swab samples from surfaces within the selected public vehicles at the Paschimanchal Bus Terminal Stop in Butwal Sub-Metropolitan City, Rupandehi, Nepal. A total of 324 swabs were collected from various high-contact surfaces, including steering wheels (S), handles (H), seat backs (SB), and seat handles (SH), across different types of vehicles such as AC Buses, Micro Buses, and Wingers. Swab specimens were collected using sterile cotton-tipped applicator sticks moistened with sterile normal saline. These swab samples were aseptically inserted into separate sterile test tubes, labeled, and transported to the Microbiology Laboratory of Crimson College of Technology, Butwal, using an icebox within 1 hour for immediate processing [21–24].

Identification of bacteria

Bacterial culture and identification were carried out by inoculating swabs collected from public vehicles surfaces onto various culture media (HiMedia Laboratories Pvt.Ltd.) like Nutrient Agar (NA), Mannitol Salt Agar (MSA), McConkey Agar (MAC), Blood Agar, Thiosulfate-Citrate-Bile Salts-Sucrose (TCBS), and Xylose Lysine Deoxycholate (XLD) agar [21,22]. Culture plates were incubation at 37 0C for 24–48 hours, depending on the bacterial species. After incubation morphological examination of bacterial colonies were conducted targeting colonies size, shape, color, margin, elevation and haemolytic patterns. Gram staining was conducted to differentiate gram-positive and gram-negative bacteria. Bacterial colonies were enumerated, and further confirmation of bacterial species was carried out through specific biochemical tests.Triple Sugar Iron (TSI) test was used to assess sugar fermentation and hydrogen sulphide producton, Voges-Proskauer (VP) and Methyl Red (MR) tests are used to detect metabolic end production; Indole test evaluated tryptophan degradation; Catalase,Oxidase and Citrate tests assessed bacterial specific enzymatic activities. All carried out tests were performed by following the microbiological procedures outlined in Bergey’s Manual of Bacteriology [21].

Antibiotic susceptibility test (AST) of the bacterial isolates

Antibiotic susceptibility testing (AST) was performed using the modified Kirby-Bauer disk diffusion method, adhering to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [25]. Antibiotic discs (HiMedia Laboratories Pvt.Ltd.) were chosen based on the type of bacterial isolates, with Gram-negative bacteria tested using discs containing Amikacin (30 µg), Cefoxitin (30 µg), Chloramphenicol (30 µg), Ciprofloxacin (5 µg), Imipenem (10 µg), Piperacillin/tazobactam (TZP) (100/10 µg), Erythromycin (15 µg), Gentamicin (10 μg), Ceftriaxone (30 µg), and Co-trimoxazole (25 µg). For Gram-positive bacteria, the discs used were Amikacin (30 µg), Amoxicillin-clavulanic acid (20/10 µg), Cefotaxime (30 µg), Ceftazidime (30 µg), Ceftriaxone (30 µg), Chloramphenicol (30 µg), Ciprofloxacin (5 µg), Co-trimoxazole (25 µg), Meropenem (10 µg), and Gentamicin (10 µg). Bacterial isolates were inoculated onto Mueller-Hingon agar culture plates and antibiotic discs were applied. Mueller-Hinton agar plates were incubated at 35 ± 20C for 16–18 hours.The diameter of the zones of inhibition around each disc were measured in millimetres and susceptibility was interpreted according to the CLSI 2022 breakpoints guidelines to classify the isolates as susceptible (s), intermediate (I) or resistant (R) for each antibiotic and bacterial species [21,26,27].

Quality assurance

Aseptic techniques were used in all the steps of specimen collection and inoculation to minimize contamination. Specimens were collected in aseptic conditions. Reagents and antimicrobial discs were checked for expiry date. Sterility of culture media was carried out by incubating 5% of the prepared media before inoculation. Escherichia coli (ATCC 25934), Staphylococcus aureus (ATCC 25955), and Pseudomonas aeruginosa (ATCC 27866) reference strains were used to control the performance of culture media and antibiotic discs to assess the quality of the general laboratory procedure.

Data analysis

Data were entered into Microsoft Excel and imported into Statistical Package for Social Sciences (SPSS) software version 21.0 for analysis. Descriptive statistics, including frequencies, percentages and proportions were calculated to summarize variables like as sample sources, vehicle types, bacterial species and antibiotic sensitivity patterns. Means and standard deviations applied to summarize for continuous variables.The chi-square test was used to determine the associations between categorical variables to identify whether bacterial contamination differed by public vehicle type and weather antibiotic resistance patterns varied among isolated bacterial species.A p-value ≤0.05 was considered as a statistically significant exploring a meaningful association between the tested variables (S1 Data).

Results

Over a one year period, a comprehensive investigation was conducted involving 81 public vehicles, comprising AC (Air Conditioner) Buses (n = 27), Micro Buses (n = 27), and Wingers (n = 27). A total of 324 swabs were meticulously collected from high contact surfaces specifically steering wheels (S), handles (H), seat backs (SB), and seat handles (SH).These locations were chosen because they are the surfaces most frequently touched by passengers and drivers, thereby presenting the highest risk of bacterial contamination due to frequent contact. Out of the 324 swabs collected, bacterial growth was observed in 262 specimens, accounting for a prevalence rate of 80.86%.

Frequency of bacterial isolates

Among the 262 bacterial isolates obtained from the swab samples, Gram-positive bacteria accounted for 148 (56.48%) of the total isolates, while Gram-negative bacteria constituted 114 (43.51%) of the isolates. The most prevalent Gram-positive bacteria species included Coagulase-negative staphylococci (CoNS) 72(27.48%), Staphylococcus aureus 52(19.84%), Bacillus spp.13 (8.02%), and Micrococcus spp.11(4.19%). Notable Gram-negative bacteria isolate comprised Escherichia coli 32 (12.21%), Klebsiella spp.26 (9.92%), Pseudomonas spp.13 (8.02%), Proteus spp.13 (8.02%), Enterobacter spp.11 (4.19%), Acinetobacter spp.10 (3.81%), and Citrobacter spp. 9 (3.43%) (Fig 1).

Fig 1. Frequency of Bacterial Isolates – This figure illustrates the distribution of various bacterial isolates obtained from swab samples.

Fig 1

Distribution of bacterial isolates between AC bus, micro bus, and winger

The distribution of bacterial isolates across different types of public vehicles, including AC Buses, Micro Buses, and Wingers, varied significantly as indicated by the calculated P-values. Coagulase-negative Staphylococci (CoNS) were presentig significantly greater degrees in the Micro Buses 32 (44.44%) than AC Buses 14 (19.44%) and Wingers 26 (36.11%) (P < 0.001). The findings can be better understood through evaluation of the proportion of types of coagulase negative Staphylococci (CoNS) for modes of transport as they differed significantly too. Staphylococcus aureus also was considerably higher in Micro Buses 22 (42.31%) than AC Buses 10 (19.23%) and Wingers 20 (38.46%) (P = 0.012). Proteus spp. occurred much more in Wingers 6 (46.15%) than AC Buses 2 (15.38%) and Micro Buses 5 (38.46%) (P = 0.023). Pseudomonas spp. occurred significantly more in Micro Buses 7 (53.85%) than Wingers 5 (38.46%) and AC Buses 1 (7.69%) (P < 0.001).Citrobacter spp. occurred significantly more in Micro Buses (N = 4), (44.44%) and Wingers (N = 4) (44.44%) than in AC Buses (N = 1) (11.11%) (p = 0.026) (Table 1).

Table 1. Distribution of bacterial isolates between AC bus, micro bus, and winger.

Bacteria AC Bus (n = 27) Microbus (n = 27) Winger (n = 27) Total (n = 81) P-value
Citrobacter spp. 1 (11.11%) 4 (44.44%) 4 (44.44%) 9 (11.11%) 0.026
Acinetobacter spp. 2 (20.00%) 3 (30.00%) 5 (50.00%) 10 (12.35%) 0.236
Micrococcus spp. 3 (27.27%) 5 (45.45%) 3 (27.27%) 11 (13.58%) 0.334
Enterobacter spp. 3 (27.27%) 3 (27.27%) 5 (45.45%) 11 (13.58%) 0.332
Bacillus spp. 3 (23.08%) 4 (30.77%) 6 (46.15%) 13 (16.05%) 0.186
Pseudomonas spp. 1 (7.69%) 7 (53.85%) 5 (38.46%) 13 (16.05%) <0.001
Proteus spp. 2 (15.38%) 5 (38.46%) 6 (46.15%) 13 (16.05%) 0.023
Klebsiella spp. 6 (23.08%) 12 (46.15%) 8 (30.77%) 26 (32.10%) 0.088
Escherichia coli 8 (25.00%) 14 (43.75%) 10 (31.25%) 32 (39.51%) 0.057
Staphylococcus aureus 10 (19.23%) 22 (42.31%) 20 (38.46%) 52 (64.20%) 0.012
CoNS 14 (19.44%) 32 (44.44%) 26 (36.11%) 72 (88.89%) <0.001

This table compares the prevalence of bacterial isolates found in different types of public transportation.

Abbreviations: AC= Air Conditioner, spp = Species, n= Total Number.

Distribution of bacterial isolates amongst various surfaces (steering-S, handle-H, seat back-SB, seat handle-SH)

Distribution of bacterial isolates across different sampling sites, namely Steering-S (steering wheels), Handle-H (handles), Seat back-SB (seat backs), and Seat handle-SH (seat handles). Each column represents the percentage of specific bacterial species found at the corresponding sampling site. For instance, in the Steering-S category, Coagulase-negative staphylococci (CoNS) constitute 13 (18.06%) of isolates, while Staphylococcus aureus (S. aureus) accounts for 11 (21.15%). Similarly, the Handle-H site shows a prevalence of 19 (26.39%) for CoNS and 13 (25.00%) for S. aureus. Notably, significant variations in bacterial distribution are observed across sampling sites, as indicated by the calculated P-values. For instance, the Seat back-SB and Seat handle-SH sites exhibit notably low P-values of 0.002 and 0.001, respectively, suggesting a statistically significant association between bacterial isolates and these particular sampling locations (Table 2).

Table 2. Distribution of Bacterial isolates amongst various surfaces.

Bacteria Steering (S) Handle (H) Seat Back (SB) Seat Handle (SH) Total
Citrobacter spp. 3 2 2 2 9
Acinetobacter spp. 2 2 2 4 10
Micrococcus spp. 3 1 3 4 11
Enterobacter spp. 1 3 3 4 11
Bacillus spp. 2 5 1 5 13
Pseudomonas spp. 3 4 1 5 13
Proteus spp. 4 4 4 1 13
Klebsiella spp. 5 8 7 6 26
Escherichia coli 11 9 2 10 32
Staphylococcus aureus 11 13 16 12 52
CoNS 13 19 18 22 72

This table details the distribution of bacterial isolates found on various surfaces: steering (S), handle (H), seat back (SB), and seat handle (SH).

Abbreviations: CoNS = Coagulase-negative staphylococci, spp = Species.

Antibiotics susceptibility profile for Gram-positive isolates

Coagulase-negative Staphylococci (CoNS) strains exhibit high sensitivity to Gentamicin 70(97.22%) and Ciprofloxacin 58(80.56%), contrasting with lower sensitivity to Piperacillin/tazobactam27 (37.50%). Staphylococcus aureus strains show comparable high sensitivity to Ciprofloxacin 44(84.62%) and Gentamicin 41(78.85%) yet demonstrate decreased sensitivity to Erythromycin 22(42.31%). Bacillus species display relatively high sensitivity to Gentamicin 11(84.62%) and Ceftriaxone 10(76.92%), while Micrococcus species exhibit exceptional sensitivity to Gentamicin 12(100.00%). Conversely, Piperacillin/tazobactam consistently reveals lower efficacy across bacterial species (Table 3).

Table 3. Antibiotics susceptibility profile for Gram-positive isolates.

SN Antibiotics CoNS (%,n = 72,S/R) S. aureus (%,n = 52, S/R) Bacillus spp (%,n = 13, S/R) Micrococcus spp (%,n = 12, S/R)
1 Amikacin 63.89 (46/26) 61.54 (32/ 20) 69.23 (9/ 4) 66.67 (8/4)
2 Cefoxitin 56.94 (41/31) 63.46 (33/19) 46.15 (6/7) 50.00 (6/6)
9 Ceftriaxone 69.44 (50/22) 57.69 (36/16) 76.92 (10/3) 75.00 (9/ 3)
3 Chloramphenicol 76.39 (55/17) 67.31 (35/17) 61.54 (8/5) 58.33 (7/5)
4 Ciprofloxacin 80.56 (58/14) 84.62 (44/8) 69.23 (9/3) 83.33 (10/2)
10 Co-trimoxazole 76.39 (55/17) 73.08 (40/12) 38.46 (5/8) 66.67 (8/4)
7 Erythromycin 56.94 (41/31) 42.31 (22/30) 23.08 (3/10) 41.67 (7/5)
8 Gentamicin 97.22 (70/2) 78.85 (41/11) 84.62 (11/2) 100.00 (12/0)
5 Imipenem 50.00 (36/36) 67.31 (35/17) 69.23 (9/4) 75.00 (9/3)
6 Piperacillin/tazobactam 37.50 (27/45) 80.77 (42/10) 76.92 (10/3) 58.33 (5/7)

This table presents the susceptibility patterns of Gram-positive bacterial isolates to various antibiotics.

Abbreviations: CoNS = Coagulase-negative staphylococci, spp = Species, S = Sensitive, R = Resistant, % = Percentage, n = Total Number.

Antibiotics susceptibility profile for Gram-negative isolates

Amikacin shows high sensitivity percentages against Escherichia coli 22 (68.8%), Klebsiella spp. 22 (84.6%), Pseudomonas spp.13 (100.0%), Proteus spp. 8 (61.5%), Enterobacter spp.11 (100.0%), Acinetobacter spp.9 (90.0%), and Citrobacter spp.8 (88.9%). Meropenem exhibits similarly high sensitivity percentages across the board, ranging from 88.5% to 100.0%, indicating efficacy against all tested organisms. Gentamicin also displays excellent sensitivity percentages, with 90.6% to 100.0% sensitivity across all organisms (Table 4).

Table 4. Antibiotic susceptibility profile for Gram-negative isolates.

Antibiotics Escherichia coli Klebsiella spp. Pseudomonas spp. Proteus spp. Enterobacter spp. Acinetobacter spp. Citrobacter spp.
(%,n = 32, S/R) (%,n = 26, S/R) (%,n = 13, S/R) (%,n = 13, S/R) (%,n = 11, S/R) (%,n = 10, S/R) (%, n = 9, S/R)
Amikacin 68.8 (22/10) 84.6 (22/4) 100.0 (13/0) 61.5 (8/5) 100.0 (11/0) 90.0 (9/1) 88.9 (8/1)
Amoxicillin-clavulanic 34.4 (11/21) 46.2 (12/14) 69.2 (9/4) 38.5 (8/5) 22.2 (2/7) 20.0 (2/8) 22.2 (2/7)
Cefotaxime 43.8 (14/18) 38.5 (10/16) 92.3 (12/1) 76.9 (10/3) 100.0 (11/0) 100.0 (10/0) 55.6 (5/4)
Ceftazidime 53.1 (17/15) 53.8 (14/12) 46.2 (6/7) 69.2 (9/4) 36.4 (4/7) 60.0 (6/4) 44.4 (4/5)
Ceftriaxone 37.5 (12/20) 61.5 (16/10) 69.2 (9/4) 76.9 (10/3) 100.0 (11/0) 100.0 (10/0) 100.0 (9/0)
Chloramphenicol 81.3 (26/6) 46.2 (12/14) 84.6 (11/2) 100.0 (13/0) 90.9 (10/1) 50.0 (5/5) 66.7 (6/4)
Ciprofloxacin 90.6 (29/3) 73.1 (19/7) 100.0 (13/0) 76.9 (10/3) 100.0 (11/0) 100.0 (10/0) 100.0 (9/0)
Co-trimoxazole 31.3 (10/22) 38.5 (10/16) 23.1 (3/10) 38.5 (5/8) 8.3 (1/12) 30.0 (3/7) 44.4 (4/5)
Gentamycin 90.6 (29/3) 100.0 (26/0) 100.0 (13/0) 100.0 (12/0) 100.0 (11/0) 100.0 (11/0) 100.0 (9/0)
Meropenem 90.6 (29/3) 88.5 (23/3) 100.0 (13/0) 100.0 (13/0) 100.0 (11/0) 100.0 (11/0) 100.0 (9/0)

This table presents the susceptibility patterns of Gram-negative bacterial isolates to various antibiotics.

Abbreviations: CoNS = Coagulase-negative staphylococc, spp = Species, S = Sensitive, R = Resistant, % = Percentage, n = Total Number.

For instance, amoxicillin-clavulanic acid shows relatively high resistance percentages against several organisms, ranging from 46.2% to 69.2%. Co-trimoxazole also demonstrates notable resistance percentages, ranging from 23.1% to 44.4%, indicating a significant proportion of organisms resistant to this antibiotic. Additionally, ceftriaxone exhibits high resistance percentages against most organisms, with 61.5% to 100.0% resistance observed.

Discussion

This study investigated the level of bacterial contamination and antibiotic resistance patterns found in public vehicles of Butwal Nepal to understand whether public transport can act as a reservoir for pathogens. It was found that 80.86% of swab samples were positive for bacterial growth and the identification stage revealed both Gram-positive and Gram-negative organisms, with Coagulase-negative staphylococci, and Staphylococcus aureus being the most prevalent Gram-positive isolates and Escherichia coli and Klebsiella spp. being the most prevalent Gram-negative organisms. The distribution of bacteria differed greatly from vehicle to vehicle, and from surface to surface. It was documented that there was strong resistance to β-lactams and co-trimoxazole, but there was still efficacy of aminoglycosides and carbapenems. The study acheived its objectives that addressed major public health concerns in the urban environment of microbial contamination and antibiotic resistant organisms in a shared transporation situation.

The levels of bacterial contamination reported in our study were similar to those reported in other countries. For example, in Accra, Ghana, Darko et al. (2021) surveyed bus surfaces and found high levels of bacterial load, including Staphylococcus spp. and enteric bacteria [2]. Birteksoz Tan and Erdogdu (2017) also reported high microbial loads on handles of public vehicles in Istanbul, Turkey, suggesting that high touch surfaces are susceptible to high levels of contamination [3]. Similar findings were reported in the Kathmandu Valley, Nepal, where Angbuhang et al. (2018) found high levels of microbial contamination on bus surfaces, which were attributed to poor levels of enforcement on sanitary practices [8]. These studies, taken as a whole, confirm that bacterial contamination of public transport vehicles is a global issue, that hygiene and sanitation policies are highly related to control of bacterial contamination.

Our study identified S. aureus and coagulase-negative Staphylococci (CoNS) as the most common Gram-positive isolates. This is in line with a Ghanaian study where S. aureus, including MRSA, was frequently isolated from public transport, raising concerns about infection risks [5]. Similarly, Kahsay et al. (2019) in Ethiopia reported both enteric bacteria and MRSA from bus surfaces, suggesting that public transport environments harbor a mixture of commensals and pathogenic organisms [12]. These results collectively highlight the role of public vehicles as reservoirs for community- and healthcare-associated pathogens, with the potential to facilitate their widespread transmission.

Among Gram-negative bacteria, E. coli and Klebsiella spp. were most frequently isolated in our study, pointing to fecal contamination and inadequate sanitation. Comparable findings were reported by UjJaman Arowan et al. (2021) in Dhaka, Bangladesh, where E. coli and other enteric pathogens were frequently detected on public transport [11]. Moreover, Fernanda et al. (2023) detected β-lactam resistance genes in bacterial isolates from Quito, Ecuador, demonstrating that transport systems may also serve as reservoirs of resistance determinants [4]. A similar study in Seoul, South Korea revealed that microbial communities on public transit carried multidrug resistance genes (Jang et al., 2022) [15]. Taken together, these findings emphasize that public transport not only facilitates bacterial transmission but also may contribute to the spread of antimicrobial resistance (AMR).

Our surface-specific findings had significant correlations with certain surfaces, particularly high-touch surfaces, including seatbacks and seat handles. Previous research from Europe has highlighted door handles and railings as hotspots for microbial risk, and highlighted concerns for these surfaces, resulting from microbial contamination from passengers [7,18]. Our data highlights the critical need for cleaning protocols for all transport vehicle surfaces, particularly high-touch surfaces, to minimize exposure risk.

In our study, antibiotic susceptibility testing indicated finding that both aminoglycosides (amikacin and gentamicin) and carbapenems (meropenem) were still the most effective agents against both Gram-positive and Gram-negative isolates. It has been reported that in Austria and India despite the well-documented problem of widespread multidrug resistance there was still a pattern of maintained sensitivity to aminoglycosides and carbapenems [16,19]. However, the high rates of resistance to β-lactams and co-trimoxazole that we found in our isolates correspond to the findings out of Ghana and Vienna that reported Enterobacteriaceae exhibiting resistance rates in excess of 50% [6,19]. Taken together these findings emphasize the growing concern of AMR in public spaces, likely a result of inappropriate antibiotic use, and insufficient environmental sanitation [13,28].

Overall the results of this study have meaningful implications for public health. Public transport vehicles serve as a vehicle and vector for transmissible pathogens and antibiotic resistant organisms; the fact that public transport represents an opportunity for common community spread is a significant findings together with integrative reviews that propose public transport to be a neglected but notable contributing factor to community-acquired infections [9,27]. This is particularly important for Nepal where public transport is deeply relied upon, and the results would urgently necessitate interventions such as disinfecting frequently used trappable surfaces on scheduled basis, education campaigns for the community, being aware of potential hygiene standards based exposure parameters in industry best practices and regulations for transport vehicles [20,29]. Additionally, ongoing reporting of resistance and ongoing surveillance in the environment for understanding and consideration in addition to clinical surveillance programs will be necessary [20,28]. This study provides useful insights into public health planning and development of targeted interventions to reduce microbial hazards and improve hygiene behaviours.

Limitations

There are a few limitations that must be acknowledged when evaluating the results of this study. To begin, the study was conducted in a single city (Butwal), and thus the results may not reflect microbial contamination patterns across all areas of Nepal. Second, while we discovered a variety of bacteria, we did not employ molecular methods (for example, PCR and sequencing) which would have provided a more precise identification and characterization for resistance genes. Third, the cross-sectional approach limits ability to investigate temporal changes in bacterial contamination across geographically distinct areas, and with different seasons. Fourth, the study focused only on bacterial contaminants and did not investigate the presence of other possible viral or fungal pathogens or contributants to transport related infections. In light of the limitations noted above, this study provides an essential baseline from which to begin to understand the microbial risks presented by public transport systems in Nepal.

Recommendations

To reduce the risk of bacterial contamination and antimicrobial resistance from public transport systems, immediately after a commitment to routine disinfecting of high touch surfaces should made, and national hygiene standards are agreed upon, monitoring of compliance with the agreed international standards is recommended. Public campaigns to improve awareness can encourage compliance with preventive behaviours, including washing hands and using hand sanitizers while travelling. Increasing public health protection can also be supported by introducing antimicrobial resistance surveillance into current National antimicrobial resistance action plans, as well as aspects of transport hygiene being included in infection prevention and stewardship plans. An attention to capacity building activities such as training and incentivising transport workers can be undertaken to contribute to meaningful sanitation improvements.

Conclusion

This study indicates that public transportation in Butwal, Nepal, presents a significant public health risk. Bacterial contamination levels were found to be high in publicly available transport vehicles surfaces, and that these surfaces had both Gram-positive and Gram-negative pathogens. The presence of multi-drug resistant bacteria also indicated the potential for public transport vehicles to act as a reservoir and vehicle for the transmission or spread of antimicrobial resistance into the community. In general, the results from this study indicated that public health interventions are needed to improve sanitation and disinfection of public transport, uphold hygiene behaviours related to transport, and implement AMR surveillance as part of public health practice. It will be important to focus attention on public health interventions in Butwal and other cities, through the use of evidence based, continuing community awareness, in order to address these issues to create a safer environment to diminish risk of infection for public health in Nepal. This issue will also require collective action from agencies of government, owners and operators of public transportation, and the community to ensure that hygiene standards are maintained, and the impacts of antimicrobial resistance are limited in their community.

Supporting information

S1 Data. Data analysis.

This dataset summarizes the analytical methods employed, including descriptive statistics, chi-square tests, and the statistical significance of relationships between variables such as public vehicle type and antibiotic resistance patterns.

(XLSX)

pgph.0006421.s001.xlsx (30.2KB, xlsx)

Acknowledgments

The author would like to acknowledge the Pokhara University Research Center (PURC) and Crimson College of Technology (CCT) for their kind support and guidance during research work.

Data Availability

All data underlying the findings of this study are fully available without restriction. The complete dataset, including all raw data points used in the analysis, has been deposited in the Zenodo public repository. https://doi.org/10.5281/zenodo.17766523.

Funding Statement

This work was supported by the Pokhara University Research Center (PURC) (Approval/Grant No. 02-2079/80) awarded to Ram Bahadur Khadka. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No commercial companies provided funding for this study, and RBK received salary support from Crimson College of Technology during the study period. The funder’s website is: https://pu.edu.np/workplaces/purc/.

References

  • 1.World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance. World Health Organization; 2024. [Google Scholar]
  • 2.Darko AO, Mariwah S, Abane AM, Amoako-Sakyi RO, Pereko KA. Public road transport system and the spread of communicable diseases: perspectives of operators and passengers in Accra, Ghana. Ghana J Geography. 2021;13(3). doi: 10.4314/gjg.v13i3.10 [DOI] [Google Scholar]
  • 3.Birteksöz AS, Erdoğdu G. Microbiological burden of public transport vehicles. Istanbul J Pharm. 2017;47(2):52–6. doi: 10.5152/IstanbulJPharm.2017.008 [DOI] [Google Scholar]
  • 4.Hernández-Alomía F, Bastidas-Caldes C, Ballesteros I, Tenea GN, Jarrín-V P, Molina CA, et al. Beta-lactam antibiotic resistance genes in the microbiome of the public transport system of Quito, Ecuador. Int J Environ Res Public Health. 2023;20(3):1900. doi: 10.3390/ijerph20031900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Haule GP, Hussein JM, Mpenda FN. Occurrence and antimicrobial susceptibility of Enterobacteriaceae from public transport in Dar es Salaam, Tanzania. Baghdad J Biochem Appl Biol Sci. 2024;5(1):36–58. doi: 10.47419/bjbabs.v5i01.265 [DOI] [Google Scholar]
  • 6.Abdulai M, Abubabakari ZI, Cobinna SJ, Oduro D. Bacteria loads of public transport in the Tamale Metropolis, Ghana. UDS Int J Dev. 2021;7(2):379–86. doi: 10.47740/492.udsijd6i [DOI] [Google Scholar]
  • 7.Appiah PO, Odoom A, Tetteh-Quarcoo PB, Kotey FCN, Donkor ES. Microbial contamination of door handles: a global systematic review and meta-analysis of public and healthcare settings. Environ Health Insights. 2025;19. doi: 10.1177/11786302251328550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Angbuhang KB, Neupane M, Adhikari A, K C B, Jha S. Detection of methicillin resistant Staphylococcus aureus in public transportation of Kathmandu Valley, Nepal. Tribhuvan Univ J Microbiol. 2018;5:51–6. doi: 10.3126/tujm.v5i0.22312 [DOI] [Google Scholar]
  • 9.Budzynski M, Luczkiewicz A, Szmaglinski J. Assessing the risk in urban public transport for epidemiologic factors. Energies. 2021;14(15):4513. doi: 10.3390/en14154513 [DOI] [Google Scholar]
  • 10.Ly Y-T, Leuko S, Moeller R. An overview of the bacterial microbiome of public transportation systems-risks, detection, and countermeasures. Front Public Health. 2024;12:1367324. doi: 10.3389/fpubh.2024.1367324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Uj Jaman Arowan SM, Das KK, Feroz F. Microbiological surveillance of air and contact surface of pubic transports with its correlation to human infection risks. Stamford J Microbiol. 2021;11(1):7–10. doi: 10.3329/sjm.v11i1.57144 [DOI] [Google Scholar]
  • 12.Kahsay AG, Asgedom SW, Weldetinsaa HL. Enteric bacteria, methicillin resistant S. aureus and antimicrobial susceptibility patterns from buses surfaces in Mekelle city, Tigray, Ethiopia. BMC Res Notes. 2019;12(1):337. doi: 10.1186/s13104-019-4366-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yeh PJ, Simon DM, Millar JA, Alexander HF, Franklin D. A diversity of antibiotic-resistant Staphylococcus spp. in a public transportation system. Osong Public Health Res Perspect. 2011;2(3):202–9. doi: 10.1016/j.phrp.2011.11.047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lutz JK, van Balen J, Crawford JM, Wilkins JR 3rd, Lee J, Nava-Hoet RC, et al. Methicillin-resistant Staphylococcus aureus in public transportation vehicles (buses): another piece to the epidemiologic puzzle. Am J Infect Control. 2014;42(12):1285–90. doi: 10.1016/j.ajic.2014.08.016 [DOI] [PubMed] [Google Scholar]
  • 15.Guevarra RB, Hwang J, Lee H, Kim HJ, Lee Y, Danko D, et al. Metagenomic characterization of bacterial community and antibiotic resistance genes found in the mass transit system in Seoul, South Korea. Ecotoxicol Environ Saf. 2022;246:114176. doi: 10.1016/j.ecoenv.2022.114176 [DOI] [PubMed] [Google Scholar]
  • 16.Nygren E, Gonzales Strömberg L, Logenius J, Husmark U, Löfström C, Bergström B. Potential sources of contamination on textiles and hard surfaces identified as high-touch sites near the patient environment. PloS One. 2023;18(7):e0287855. doi: 10.1371/journal.pone.0287855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Conceição T, Diamantino F, Coelho C, de Lencastre H, Aires-de-Sousa M. Contamination of public buses with MRSA in Lisbon, Portugal: a possible transmission route of major MRSA clones within the community. PLoS One. 2013;8(11):e77812. doi: 10.1371/journal.pone.0077812 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sultan N, Seyoum A, Ayele F, Mekonnnen GK. Pathogenic bacterial profile, associated factors, and antimicrobial susceptibility patterns in intra-city public transport in Harar City, Eastern Ethiopia. Front Public Health. 2025;13:1521479. doi: 10.3389/fpubh.2025.1521479 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Simões RR, Aires-de-Sousa M, Conceição T, Antunes F, da Costa PM, de Lencastre H. High prevalence of EMRSA-15 in Portuguese public buses: a worrisome finding. PLoS One. 2011;6(3):e17630. doi: 10.1371/journal.pone.0017630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Stephenson RE, Gutierrez D, Peters C, Nichols M, Boles BR. Elucidation of bacteria found in car interiors and strategies to reduce the presence of potential pathogens. Biofouling. 2014;30(3):337–46. doi: 10.1080/08927014.2013.873418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bergey DH. Bergey’s manual of determinative bacteriology. Lippincott Williams & Wilkins; 1994. https://books.google.com.np/books?hl=en&lr=&id=jtMLzaa5ONcC&oi=fnd&pg=PA1&dq=Bergey%E2%80%99s±Manual±of±Determinative±Bacteriology&ots=HsaY77jTqk&sig=5e-wPsEWOB98cbeOCoMLhoTufIM&redir_esc=y#v=onepage&q=Bergey%E2%80%99s%20Manual%20of%20Determinative%20Bacteriology&f=false [Google Scholar]
  • 22.Boom FA, Brun PPHL, Bühringer S, Touw DJ. Microbiological monitoring during aseptic handling: methods, limits and interpretation of results. Eur J Pharm Sci. 2020;155:105540. doi: 10.1016/j.ejps.2020.105540 [DOI] [PubMed] [Google Scholar]
  • 23.Kahlmeter G, Giske CG, Kirn TJ, Sharp SE. Point-counterpoint: differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute recommendations for reporting antimicrobial susceptibility results. J Clin Microbiol. 2019;57(9):e01129-19. doi: 10.1128/JCM.01129-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kassim A, Omuse G, Premji Z, Revathi G. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study. Ann Clin Microbiol Antimicrob. 2016;15:21. doi: 10.1186/s12941-016-0135-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bayot ML, Bragg BN. Antimicrobial susceptibility testing. StatPearls. StatPearls Publishing; 2024. [PubMed] [Google Scholar]
  • 26.Syal K, Mo M, Yu H, Iriya R, Jing W, Guodong S, et al. Current and emerging techniques for antibiotic susceptibility tests. Theranostics. 2017;7(7):1795–805. doi: 10.7150/thno.19217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Mitic Culafic D, et al. Antimicrobial susceptibility testing: a comprehensive review of currently used methods. Antibiotics. 2022;11(4):427. doi: 10.3390/antibiotics11040427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Nasir ZA, Campos LC, Christie N, Colbeck I. Airborne biological hazards and urban transport infrastructure: current challenges and future directions. Environ Sci Pollut Res Int. 2016;23(15):15757–66. doi: 10.1007/s11356-016-7064-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Khadka RB, Karki K, Pandey J, Gyawali R, Chaudhary GP. Strengthening global health resilience: Marburg virus-like particle vaccines and the One Health approach. Sci One Health. 2024;3:100076. doi: 10.1016/j.soh.2024.100076 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. 2026 May 8;6(5):e0006421. doi: 10.1371/journal.pgph.0006421.r001

Author response to Decision Letter 0


Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

7 Jun 2025

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0006421.r002

Decision Letter 0

Delfina Fernandes Hlashwayo

12 Aug 2025

PGPH-D-25-01435

Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal

PLOS Global Public Health

Dear Dr. KHADKA,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please review in detail each comment from both reviewers, both those contained in the attached file and those included in the text of this email, and provide an explicit, point-by-point response indicating how each comment is addressed in the revised manuscript.

Please submit your revised manuscript by Sep 26 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Delfina Fernandes Hlashwayo, Ph.D.

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect.

2. Please provide a/amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

**Please only choose the relevant sentences from below**

a. Please clarify all sources of funding (financial or material support) for your study. List the grants (with grant number) or organizations (with url) that supported your study, including funding received from your institution.

b. State the initials, alongside each funding source, of each author to receive each grant.

c. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

d. If any authors received a salary from any of your funders, please state which authors and which funders.

If you did not receive any funding for this study, please simply state: “The authors received no specific funding for this work.”

3. In the online submission form, you indicated that “The data supporting the findings of this study are available upon request from the corresponding author”.

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either

a. In a public repository,

b. Within the manuscript itself, or

c. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.-->

Reviewer #1: Partly

Reviewer #2: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously?-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

Reviewer #2: No

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: During the reading of the manuscript, I noted several positive aspects, including the clarity of presentation, the use of accessible language by the authors, and the overall logical structure of the manuscript, which aligns well with the requirements for publication in PLOS Global Public Health.

However, there are several areas that require improvement or clarification. I highlight the following:

• Methodology (Line 97): The authors mention the tests used for bacterial identification and refer to the Bergey’s Manual of Bacteriology for further procedural details. However, they do not describe how these tests were conducted in the context of their study. It would be more appropriate to briefly describe the procedures rather than simply citing the manual.

• Line 112: Although the antimicrobial susceptibility testing (AST) procedure is generally well described, it would be beneficial to include more specific details about the incubation conditions, particularly the temperature and duration.

• Line 115: The authors state that the diameters of inhibition zones around each disc were measured and interpreted according to CLSI guidelines. However, it would be helpful to specify the exact criteria or breakpoints from the CLSI used for interpretation.

• Line 124 (Data analysis): The manuscript mentions the use of SPSS for data analysis, but it is unclear what specific information or variables were analyzed using this software, and how the variables were classified. Additionally, the purpose of the chi-square test should be clarified, what associations were being tested?

• Line 139 (Sampling strategy): The authors state that swab samples were collected from different parts of the buses. It would strengthen the manuscript to explain the rationale for selecting these particular sites. While readers with microbiological background may infer the reasoning (i.e., higher likelihood of contamination), this should be explicitly stated for the benefit of a broader audience.

• Line 142 (Graph of gram-negative bacteria): It is suggested that the bacterial frequency values be reordered from lowest to highest (or vice versa), for consistency and improved readability, as was done with gram-positive bacteria.

• Graph design: In the graph showing the distribution of bacteria, it would be clearer to use distinct colors to differentiate between sampling locations such as the steering wheel and seat handle.

• Results section: While the manuscript describes the bacterial analysis, no images or visual documentation of the findings are provided. Including representative images (e.g., culture plates or microscopic images) would add value and help validate the results.

• Ethics approval: Although the authors state that ethical approval was obtained from the Pokhara University Research Center, the ethics approval number is missing. As per the journal’s policy, this information should be clearly included in the manuscript.

• References: The journal follows the Vancouver referencing style, but several references in the manuscript require formatting corrections, particularly regarding journal titles, article titles, punctuation, and consistency in DOI or URL presentation. Adjustments are necessary to ensure full compliance with the journal’s style guide.

Reviewer #2: I recommend revision of the manuscript. Due to the detailed nature of my comments, I have included them in the attached file. The comments address issues related to citation accuracy, clarity of the results and discussion section, reference formatting, and data presentation. I encourage the authors to review the suggestions carefully and revise the manuscript accordingly

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: Yes:Nicole De Sérgio João Olim Freitas

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments- Manuscript PGPH-D-25-01435.docx

pgph.0006421.s002.docx (16.8KB, docx)
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0006421.r004

Decision Letter 1

Delfina Hlashwayo

20 Oct 2025

PGPH-D-25-01435R1

Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal

PLOS Global Public Health

Dear Dr. KHADKA,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 04 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Delfina Fernandes Hlashwayo, Ph.D.

Academic Editor

PLOS Global Public Health

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

-->2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.-->

Reviewer #1: Partly

Reviewer #2: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously?-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

Reviewer #2: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The manuscript presents improvements in methodology, statistical analysis, clarity, ethics, and overall formatting, reflecting significant effort by the authors. However, there are still minor gaps that must be addressed for publication in PLOS Global Public Health.

Methodology (point 97): The authors added details on the tests used for bacterial identification, according to Bergey's Manual of Bacteriology, which shows that the methodology is now well described and follows expected standards.

In point 112: In the AST procedure for isolated bacteria, the text now specifies that the plates were incubated at 35 ± 2°C for 16–18 hours, which was previously not mentioned in this point.

In point 115: The specific criteria used to interpret the diameter of the inhibition zones around each disk and how this was measured were described, specifying the susceptible, intermediate, and resistant categories, according to CLSI guidelines.

In point 124: Which corresponds to data analysis, the authors explain that the data were processed in SPSS 21.0, using descriptive statistics and the chi-square test to assess associations between categorical variables (e.g., vehicle type and bacterial presence), which was not previously mentioned.

In point 139: Which is the results section, the authors mention having collected samples from different contact surfaces; however, they continue without justifying the reason for choosing these locations for the lay reader. I recommend including a brief sentence explaining that these locations were chosen because they are the surfaces with the highest risk of contamination due to frequent contact with passengers.

In point 142: I suggested that, in the frequency graph of gram-negative bacteria, their total values follow an order from lowest to highest, and so on, for better organization, as in the gram-positive bacteria section. However, the graph remains without the ordering of the values as suggested.

Graphic design: In graph 2, which shows the distribution of bacteria on different surfaces, I suggested color-coding the steering wheel and seat handle, which would facilitate visual identification. Therefore, I recommend this change.

Results section: In the bacterial analysis, no images are provided to support or represent the results. Including these would be important to validate the results presented. According to the journal's guidelines, images should be uploaded in a separate file from the manuscript, allowing them to be included as supplementary material.

Ethics approval: The authors added details regarding the ethics approval number (02-2079/80), along with a note that no human or animal data were used.

References: The references have been revised and largely follow the Vancouver format, but there are still minor duplications and inconsistencies in some links.

Reviewer #2: After a detailed review of the revised manuscript, I found that the comments and suggestions provided by the reviewers have not been adequately addressed. Furthermore, a response document to the reviewers was not submitted. The manuscript does not show significant changes in relation to the critical observations made, and, for this reason, it cannot be recommended for publication in its current version.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

-->Figure Resubmissions:

-->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->-->

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.-->

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0006421.r006

Decision Letter 2

Sarah Jose

25 Nov 2025

PGPH-D-25-01435R2

Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal

PLOS Global Public Health

Dear Dr. KHADKA,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address the reviewer's concerns in your revised manuscript, providing a point-by-point response to their comments upon resubmission.

Please submit your revised manuscript by Jan 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Sarah Jose, Ph.D.

Staff Editor

PLOS Global Public Health

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #2: (No Response)

**********

-->2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.-->

Reviewer #2: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously?-->

Reviewer #2: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: No

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #2: (No Response)

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #2: Thank you for the current version. the manuscript has improved significantly. In the previous version, the manuscript had continuous line numbering, but it was not applied throughout the entire document, in the current version, there is no line numbering at all, which makes the revision process difficult. I kindly request that the authors apply continuos line numbering to the entire manuscript.

Please specify exactly in which repository the database is available, and, if possible, provide the acess link to the database.

Review the materials an methods section and clarify whether the study period was from June 2023 to July 2024, or from June 2021 to February 2022 as stated in the response letter. There is discrepancy between the two description.

Review the reference list, as it requires more attetion and clarify.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

-->Figure Resubmissions:

-->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->-->

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.-->

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0006421.r008

Decision Letter 3

Hossam M Ashour

26 Dec 2025

-->-->-->PGPH-D-25-01435R3-->-->Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal-->-->PLOS Global Public Health

Dear Dr. KHADKA,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we have decided that your manuscript does not meet our criteria for publication and must therefore be rejected.

We are sorry that we cannot be more positive on this occasion. We very much appreciate your wish to present your work in one of PLOS's Open Access publications. Thank you for your support, and we hope that you will consider PLOS Global Public Health for other submissions in the future.

Yours sincerely,

Jay-ar Formentera Medes

Support Staff - Editorial

PLOS Global Public Health

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]-->-->-->

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0006421.r010

Decision Letter 4

Julia Robinson

20 Apr 2026

Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal

PGPH-D-25-01435R4

Dear Mr KHADKA,

We are pleased to inform you that your manuscript 'Bacterial Diversity and Antibiotic Susceptibility Profile of the Isolates from Public Vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Julia Robinson

Executive Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. Data analysis.

    This dataset summarizes the analytical methods employed, including descriptive statistics, chi-square tests, and the statistical significance of relationships between variables such as public vehicle type and antibiotic resistance patterns.

    (XLSX)

    pgph.0006421.s001.xlsx (30.2KB, xlsx)
    Attachment

    Submitted filename: Comments- Manuscript PGPH-D-25-01435.docx

    pgph.0006421.s002.docx (16.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pgph.0006421.s004.docx (17.4KB, docx)
    Attachment

    Submitted filename: Rebuttal Letter Response to Reviewer 1.docx

    pgph.0006421.s005.docx (15.8KB, docx)
    Attachment

    Submitted filename: Rebuttal Letter Response to Reviewer 2.docx

    pgph.0006421.s006.docx (15.3KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_4.docx

    pgph.0006421.s007.docx (14.6KB, docx)

    Data Availability Statement

    All data underlying the findings of this study are fully available without restriction. The complete dataset, including all raw data points used in the analysis, has been deposited in the Zenodo public repository. https://doi.org/10.5281/zenodo.17766523.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES